Rchr
J-GLOBAL ID:200901035418158812   Update date: Nov. 21, 2024

Nakayama Keiichi

ナカヤマ ケイイチ | Nakayama Keiichi
Affiliation and department:
Job title: Professor
Homepage URL  (2): https://nakayama-lab.org/https://nakayama-lab.org/en/
Research field  (3): Immunology ,  Cell biology ,  Molecular biology
Research keywords  (4): 細胞生物学 ,  分子生物学 ,  Cell Biology ,  Molecular Biology
Research theme for competitive and other funds  (65):
  • 2023 - 2026 幹細胞における時空間リプログラミングの機構解明と疾患との関わりの研究
  • 2018 - 2023 幹細胞における細胞周期の制御と代謝系との連関に関する総合的研究
  • 2017 - 2022 Trans-omic analysis of metabolic adaptation
  • 2017 - 2018 がん細胞の代謝アダプテーション
  • 2017 - 2018 代謝リモデリングによる適者生存メカニズムの研究
Show all
Papers (490):
  • Daisuke Koga, Shogo Nakayama, Tsunaki Higa, Keiichi I Nakayama. Identification and characterization of an enhancer element regulating expression of Cdkn1c (p57 gene). Genes to cells : devoted to molecular & cellular mechanisms. 2024
  • Saori Motomura, Kanae Yumimoto, Takeshi Tomonaga, Keiichi I Nakayama. CRL2KLHDC3 and CRL1Fbxw7 cooperatively mediate c-Myc degradation. Oncogene. 2024
  • Hideo Hagihara, Hirotaka Shoji, Satoko Hattori, Giovanni Sala, Yoshihiro Takamiya, Mika Tanaka, Masafumi Ihara, Mihiro Shibutani, Izuho Hatada, Kei Hori, et al. Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment. eLife. 2024. 12
  • Toshiro Moroishi, Chanida Thinyakul, Yasuhisa Sakamoto, Mayuko Shimoda, Yanliang Liu, Suyanee Thongchot, Omnia Reda, Akihiro Nita, Romgase Sakamula, Somponnat Sampattavanich, et al. Hippo pathway in cancer cells modulates tumor microenvironment by inducing immunosuppressive NCAM1+αSMA+ fibroblasts. Research Square. 2024
  • Miyuki Nomura, Mai Ohuchi, Yoshimi Sakamoto, Kei Kudo, Keisuke Yaku, Tomoyoshi Soga, Yuki Sugiura, Mami Morita, Kayoko Hayashi, Shuko Miyahara, et al. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma. Nature communications. 2023. 14. 1. 8095-8095
more...
MISC (36):
  • 松本有樹修, 市原知哉, 西田紘士, 今見考志, 石濱泰, 中山敬一. Combinatorial analysis of translatome and proteome unveils the importance of hidden ORFs. 日本分子生物学会年会プログラム・要旨集(Web). 2021. 44th
  • 市原知哉, 松本有樹修, 西田紘士, 今見孝志, 石濱泰, 中山敬一. Molecular mechanism and biological significance of non-AUG translation initiation revealed by precise identification of translation initiation sites. 日本分子生物学会年会プログラム・要旨集(Web). 2021. 44th
  • 松崎 芙美子, 松本 雅記, 中山 敬一. がん代謝. がん分子標的治療. 2014. 12. 2. 175-180
  • Surveys for mTOR Targets by Proteomic Analysis. 2012. 31. 12. 1360-1367
  • Proteomics for the study on cell cycle regulation. Cell technology. 2009. 28. 1. 59-64
more...
Education (4):
  • 1986 - 1990 Juntendo University
  • - 1990 Juntendo University Graduate School, Division of Medicine
  • 1980 - 1986 Tokyo Medical and Dental University Faculty of Medicine School of Medicine
  • - 1986 Tokyo Medical and Dental University Faculty of Medicine
Professional career (1):
  • (BLANK)
Work history (8):
  • 2024/10 - 現在 Institute of Science Tokyo Laboratory of Anticancer Strategies, Advanced Research Initiative Professor
  • 2023/04 - 2024/09 Tokyo Medical and Dental University Laboratory of Anticancer Strategies, TMDU Advanced Research Institute Professor
  • 2009/10 - 2024/03 Kyushu University Medical Institute of Bioregulation
  • 1996/10 - 2009/04 Kyushu University Medical Institute of Bioregulation
  • 1995/07 - 1996/09 (株)日本ロシュ研究所 主幹研究員
Show all
Committee career (2):
  • 2005 - 2006 日本分子生物学会 評議員
  • 2005 - 日本癌学会 評議員
Awards (9):
  • 2022/11 - Mochida Memorial Foundation for Medical and Pharmaceutical Research Mochida Memorial Award
  • 2021/03 - Medal with Purple Ribbon
  • 2018/12 - Yasuda Medical Prize
  • 2018/06 - Kobayashi Foundation for Cancer Research Kobayashi Foundation Cancer Science Award
  • 2011/02 - 第27回井上学術賞 細胞周期制御因子のユビキチン依存性分解に関わる研究
Show all
Association Membership(s) (5):
日本プロテオーム学会 ,  日本癌学会 ,  日本分子生物学会 ,  日本癌学会 ,  日本分子生物学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page